KEIO RESEARCHERS INFORMATION SYSTEM

Profile Summary 【 Display / hide 】

Profile Summary 【 Display / hide 】

• 医学の進歩に伴い、個々の心血管疾患の病態理解が深まり、心不全領域において個別化医療を実現すべく研究を進めています。また、個々の患者さんのニーズに合わせた「患者中心の医療(Patient-Centered Care)」を実践するため、現代的な枠組み構築(多職種連携やICT利活用)にも力を注いでいます。

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士（医学）, Keio University, 2017.03

Research Areas 【 Display / hide 】

Research Areas 【 Display / hide 】

• Life Science / Cardiology (Heart Failure)

• Life Science / Cardiology (腫瘍循環器学)

• Life Science / Sports sciences (心臓リハビリテーション)

Research Keywords 【 Display / hide 】

Research Keywords 【 Display / hide 】

• Heart Failure

• Personalized Medicine

• Patient Centered Care

• Patient Reported Outcome [PRO]

• 腫瘍循環器学（Onco-Cardiology）

display all >>

Books 【 Display / hide 】

Books 【 Display / hide 】

• 心不全診療Controversy

  河野隆志, 白石泰之（共編）, 中外医学社, 2023.10,  Page： 262

• 心不全治療薬の考え方, 使い方（改訂2版）

  齋藤秀輝, 鍋田 健, 柴田 龍宏（共著）, 中外医学社, 2023.10,  Page： 331

  Scope: 3章 利尿薬：1. ループ利尿薬 および 2. サイアザイド系利尿薬

• 最新主要文献とガイドラインでみる 循環器内科学レビュー 2022-'23

  清水 渉（共著）, 総合医学社, 2021.11,  Page： 413

  Scope: III章 慢性心不全：LVEFの保たれた心不全（HFpEF）患者の治療戦略

• 循環器診療エッセンシャル

  永井 利幸（共著）, 南江堂, 2022.03,  Page： 260

  Scope: 治療編：エビデンスを踏まえた治療アプローチ「4. 急性心不全」

• 心不全診療アップグレード

  佐藤 幸人（共著）, 日本医事新報社, 2021.03,  Page： 283

  Scope: 1章 心不全の疫学データの読み方・考え方

display all >>

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Hospital Variability in the Use of Vasoactive Agents in Patients Hospitalized for Acute Decompensated Heart Failure for Clinical Phenotypes

  Shiraishi Y, Niimi N, Kohsaka S, Harada K, Kohno T, Takei M, Jimba T, Nakano H, Matsuda J, Shindo A, Kitano D, Tsukamoto S, Koba S, Yamamoto T, Takayama M

  Circulation: Cardiovascular Quality and Outcomes  2024.12

  Research paper (scientific journal), Lead author, Accepted

• Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients

  Shiraishi Y, Ikemura N, Urashima M, Kohno T, Nakano S, Tanaka T, Nagatomo Y, Ikoma T, Ono T, Numasawa Y, Sakamoto M, Nishikawa K, Takei M, Hakuno D, Nakamaru R, Ueda I, Kohsaka S

  BMJ open (BMJ Open)  14 ( 2 ) e076519 2024.02

  Research paper (scientific journal), Lead author, Accepted

  　View Summary

  Introduction The current guidelines strongly recommend early initiation of multiple classes of cardioprotective drugs for patients with heart failure with reduced ejection fraction to improve prognosis and health status. However, evidence on the optimal sequencing of approved drugs is scarce, highlighting the importance of individualised treatment plans. Registry data indicate that only a portion of these patients can tolerate all four recommended classes, underscoring the need to establish the favoured sequence when using these drugs. Additionally, the choice between long-acting and short-acting loop diuretics in the present era remains uncertain. This is particularly relevant given the frequent use of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter 2 inhibitor, both of which potentiate natriuretic effects. Methods and analysis In a prospective, randomised, open-label, blinded endpoint method, LAQUA-HF (Long-acting vs short-acting diuretics and neurohormonal Agents on patients' QUAlity-of-life in Heart Failure patients) will be a 2×2 factorial design, with a total of 240 patients randomised to sacubitril/valsartan versus dapagliflozin and torsemide versus furosemide in a 1:1 ratio. Most enrolment sites have participated in an ongoing observational registry for consecutive patients hospitalised for heart failure involved dedicated study coordinators, and used the same framework to enrol patients. The primary endpoint is the change in patients' health status over 6 months, defined by the Kansas City Cardiomyopathy Questionnaire. Additionally, clinical benefit at 6 months defined as a hierarchical composite endpoint will be assessed by the win ratio as the secondary endpoint. Ethics and dissemination The medical ethics committee Keio University in Japan has approved this trial. All participants provide written informed consent prior to study entry. The results of this trial will be disseminated in one main paper and additional papers on secondary endpoints and subgroup analyses. Trial registration number UMIN000045229

  • Access to Document (DOI)

• Sweat lactate sensor for detecting anaerobic threshold in heart failure: a prospective clinical trial (LacS-001)

  Katsumata Y, Muramoto Y, Ishida N, Takemura R, Nagashima K, Ikoma T, Kawamatsu N, Araki M, Goda A, Okawara H, Sawada T, Ichihara Y, Hattori O, Yamaoka K, Seki Y, Ryuzaki T, Ikura H, Nakashima D, Nagura T, Nakamura M, Sato K, Shiraishi Y

  Scientific Reports 14 ( 1 ) 18985 2024.12

  Research paper (scientific journal), Last author, Accepted

  　View Summary

  A simple method for determining the anaerobic threshold in patients with heart failure (HF) is needed. This prospective clinical trial (LacS-001) aimed to investigate the safety of a sweat lactate-monitoring sensor and the correlation between lactate threshold in sweat (sLT) and ventilatory threshold (VT). To this end, we recruited 50 patients with HF and New York Heart Association functional classification I–II (mean age: 63.5 years, interquartile range: 58.0–72.0). Incremental exercise tests were conducted while monitoring sweat lactate levels using our sensor. sLT was defined as the first steep increase in lactate levels from baseline. Primary outcome measures were a correlation coefficient of ≥ 0.6 between sLT and VT, similarities as assessed by the Bland–Altman analysis, and standard deviation of the difference within 15 W. A correlation coefficient of 0.651 (95% confidence interval, 0.391–0.815) was achieved in 32/50 cases. The difference between sLT and VT was −4.9 ± 15.0 W. No comparative error was noted in the Bland–Altman plot. No device-related adverse events were reported among the registered patients. Our sweat lactate sensor is safe and accurate for detecting VT in patients with HF in clinical settings, thereby offering valuable additional information for treatment.

  • Access to Document (DOI)

• Improved prediction of sudden cardiac death in patients with heart failure through digital processing of electrocardiography.

  Shiraishi Y, Goto S, Niimi N, Katsumata Y, Goda A, Takei M, Saji M, Sano M, Fukuda K, Kohno T, Yoshikawa T, Kohsaka S

  EP Europace : Journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 25 ( 3 ) 922 - 930 2023.01

  Research paper (scientific journal), Lead author, Corresponding author, Accepted,  ISSN  1099-5129

  　View Summary

  Aims: Available predictive models for sudden cardiac death (SCD) in heart failure (HF) patients remain suboptimal. We assessed whether the electrocardiography (ECG)-based artificial intelligence (AI) could better predict SCD, and also whether the combination of the ECG-AI index and conventional predictors of SCD would improve the SCD stratification among HF patients.
  
  Methods and results: In a prospective observational study, 4 tertiary care hospitals in Tokyo enrolled 2559 patients hospitalized for HF who were successfully discharged after acute decompensation. The ECG data during the index hospitalization were extracted from the hospitals' electronic medical record systems. The association of the ECG-AI index and SCD was evaluated with adjustment for left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) class, and competing risk of non-SCD. The ECG-AI index plus classical predictive guidelines (i.e. LVEF ≤35%, NYHA Class II and III) significantly improved the discriminative value of SCD [receiver operating characteristic area under the curve (ROC-AUC), 0.66 vs. 0.59; P = 0.017; Delong's test] with good calibration (P = 0.11; Hosmer-Lemeshow test) and improved net reclassification [36%; 95% confidence interval (CI), 9-64%; P = 0.009]. The Fine-Gray model considering the competing risk of non-SCD demonstrated that the ECG-AI index was independently associated with SCD (adjusted sub-distributional hazard ratio, 1.25; 95% CI, 1.04-1.49; P = 0.015). An increased proportional risk of SCD vs. non-SCD with an increasing ECG-AI index was also observed (low, 16.7%; intermediate, 18.5%; high, 28.7%; P for trend = 0.023). Similar findings were observed in patients aged ≤75 years with a non-ischaemic aetiology and an LVEF of >35%.
  
  Conclusion: To improve risk stratification of SCD, ECG-based AI may provide additional values in the management of patients with HF.

  • Access to Document (DOI)

• Catheter ablation for patients with atrial fibrillation and heart failure with reduced and preserved ejection fraction: insights from the KiCS-AF multicentre cohort study

  Shiraishi Y, Kohsaka S, Ikemura N, Kimura T, Katsumata Y, Tanimoto K, Suzuki M, Ueda I, Fukuda K, Takatsuki S

  EP Europace : Journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 25 ( 1 ) 83 - 91 2022.06

  Research paper (scientific journal), Lead author, Accepted,  ISSN  1099-5129

  　View Summary

  Aims: The usefulness of catheter ablation (CA) for atrial fibrillation (AF) across a broad spectrum of heart failure (HF) patients remains to be established. We assessed the association of CA with both health-related quality of life (QoL) and cardiovascular events among HF patients with reduced and preserved left ventricular ejection fraction (LVEF) in an 'all-comer' outpatient-based AF registry.
  
  Methods and results: Of 3303 patients with AF consecutively enrolled in a retrospective multicentre registry that mandated the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire at registration and 1-year follow-up, we extracted data from 530 patients complicating clinical HF. The association between CA and both 1-year change in AFEQT Overall Summary (AFEQT-OS) scores and 2-year composite clinical outcomes (including all-cause death, stroke, and HF hospitalization) was assessed by multivariable analyses. The median duration of AF was 108 days (52-218 days), and 83.4% had LVEF >35%. Overall, 75 patients (14.2%) underwent CA for AF within 1-year after registration. At 1-year follow-up, 67.2% in the ablation group showed clinically meaningful improvements of ≥ 5 points in AFEQT-OS score than 47.8% in the non-ablation group {adjusted odds ratio, 2.03 [95% confidence interval (CI): 1.13-3.64], P = 0.017}. Furthermore, the composite endpoint of all-cause death, stroke, and HF hospitalization occurred less frequently in the ablation group than the non-ablation group [adjusted hazard ratio, 0.27 (95% CI: 0.09-0.86), P = 0.027].
  
  Conclusion: Among AF-HF patients, CA was associated with improved QoL and lower risk of cardiovascular events against drug therapy alone, even for patients with mildly reduced and preserved LVEF.

  • Access to Document (DOI)

display all >>

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• 【腫瘍循環器学-新しい学際領域の最新知見-】CTR-CVTの病態と機序　アントラサイクリン心筋症の病態と機序

  白石 泰之, 北方 博規, 家田 真樹

  日本臨床 ((株)日本臨床社)  82 ( 増刊2 腫瘍循環器学 ) 60 - 66 2024.04

  Lead author, Corresponding author,  ISSN  0047-1852

• 【今だからこそ聞きたい心不全診療のこと。】心不全研究のプール解析で注意すべき点　LVEF spectrumって何?

  白石 泰之

  循環器ジャーナル ((株)医学書院)  71 ( 2 ) 252 - 258 2023.04

  ISSN  2432-3284

  　View Summary

  ＜文献概要＞POINT　・複数の試験を集めたプール解析は,データが増えることで検出力が上がり,より信頼度の高い結果を得ることができる.・特定の解析集団での治療効果などを見るためには,各集団での被験者数・イベント数が十分確保されていることがポイントとなる.

• 【循環器学2021年の進歩】心不全診療の進歩 ～心不全の新規薬物療法と心筋再生医療への期待～

  白石 泰之, 福田 恵一

  循環器専門医 ((一社)日本循環器学会)  30   88 - 94 2021.08

  Lead author,  ISSN  0918-9599

• 【心不全急性期治療の循環管理】時間軸に基づく急性心不全治療

  白石 泰之

  INTENSIVIST（特集: 循環器集中治療 Critical Care Cardiology） ((株)メディカル・サイエンス・インターナショナル)  13 ( 1 ) 17 - 27 2021.01

  ISSN  1883-4833

  　View Summary

  ＜文献概要＞心不全診療にかかる医療面および社会・経済面での負担は莫大であり,今後しばらくは増えることはあっても減ることはない。心不全は増悪と好転を繰り返しながら慢性的に進行する症候群であり,安定期(慢性期)と増悪期(急性期)でその治療に対する考え方は異なる。心不全の急性期治療の選択肢はここ四半世紀で大きな変化はないが,ほかの循環器救急疾患と同様に「時間軸」の重要性が徐々に認識され,日本を含む世界の心不全診療ガイドラインのなかで早期診断・早期介入が強調されるに至っている。心不全急性期においては,うっ血と組織低灌流という2つの病態に対して的確な把握と対応をし,すみやかに血行動態を安定化させ,その後の慢性期治療(予後改善をめざした)へつなげていくことが肝要である。

• 【心不全の疫学】心不全予後予測スコアとその使い方 ～効果的かつ効率的な医療を実践するために～

  白石 泰之

  Hospitalist（特集: 心不全） ((株)メディカル・サイエンス・インターナショナル)  6 ( 4 ) 793 - 805 2018.12

  ISSN  2188-0409

  　View Summary

  ＜文献概要＞Summary　●心不全患者数は向こう10〜20年間は増加の一途をたどり,さらに患者の高齢化が劇的に進んでいる。日本の心不全患者の入院期間は依然として世界標準よりも長いが(15日前後),長期予後は欧米諸国に比べると良好である。●年齢や血圧,尿素窒素,血中ナトリウム濃度,そしてBNP/NT-proBNP値などが心不全患者における単独の強力な予後予測因子である。●心不全リスクモデルのなかで,GWTG-HF Risk ScoreあるいはSeattle Heart Failure Model, MAGGIC Heart Failure Risk Scoreは,日本人における当てはまりが確認されており,実際に臨床現場で使用することも可能である。●いかに熟練の医師といえども,心不全患者の予後予測は困難な場合も多く,リスクモデルによる客観的な予後予測は有用である。予後予測(リスク評価)は医療者,患者の治療方針あるいは意思決定の支柱であり,効果的かつ効率的な医療の実践のためには,リスクモデルを用いた評価が不可欠である。

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• 身体診察動画とAIを応用した血行動態評価

  白石泰之, 市原裕美子, 後藤信一, 勝俣良紀, 姫野優貴弘, 平出貴裕, 香坂俊, 家田真樹

  第28回 日本心不全学会学術集会 , 

  2024.10

  , 

  Symposium, workshop panel (public)

• Hospital Variability in the Use of Vasoactive Agents in Patients Hospitalized for Acute Decompensated Heart Failure: Clinical Phenotypes and Therapeutic Approaches

  白石泰之, 新美望, 香坂俊, 原田和昌, 木庭新治, 北野大輔, 中野宏己, 河野隆志, 神馬崇宏, 塚本茂人, 進藤彰人, 松田淳也, 山本剛, 高山守正

  第28回 日本心不全学会学術集会, 

  2024.10

  , 

  Symposium, workshop panel (public)

• 働き方改革後の臨床研究ネットワーク構築：Registry-based RCT の事例から

  白石 泰之

  第72回 日本心臓病学会学術集会, 

  2024.09

  , 

  Symposium, workshop panel (public)

• Improved prediction of sudden cardiac death in patients with heart failure through digital processing of electrocardiography

  Shiraishi Y, Kohsaka S, Nakamaru R, Kohno T, Yoshikawa T, Ieda M

  第88回 日本循環器学会学術集会, 

  2024.03

  , 

  Symposium, workshop panel (public)

• Risk-based Approach in Heart Failure

  白石 泰之

  第27回 日本心不全学会学術集会, 

  2023.10

  , 

  Symposium, workshop panel (nominated)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• 心不全患者に対する、身体診察動画とAIを用いた非侵襲的うっ血評価技術の開発

  2023.04

  -

  Present

  日本学術振興会, 科学研究費助成事業, 若手研究, Research grant, Principal investigator

• 心血管疾患に対する、運動支援プログラムに関する研究開発

  2022.10

  -

  Present

  AMED, 循環器疾患・糖尿病等生活習慣病対策実用化研究事業, 生活習慣病の予防・診断・治療のための医療機器開発に関する研究, Commissioned ｒesearch, Coinvestigator(s)

• 高齢がん患者の食生活と身体活動に着眼したがん・心血管セルフケアプログラムの有効性

  2024.04

  -

  2029.03

  Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), No Setting

  　View Summary

  高齢がん患者はがんよりもがん治療関連心血管疾患で死亡する割合が高く、双方の適切な管理が不可欠である。本研究はがんと心血管疾患の観点から高齢がん患者が安全で優しいセルフケアプログラム開発を目指す。食生活と身体活動に着眼したがん・心血管セルフケアプログラムを高齢者と協働開発し、専門家の科学的根拠と高齢がん患者の視点を統合し、内容妥当性を検証する。最終段階ではプログラムの実用可能性や有効性評価まで行う。

• 性差を考慮した疾患の予防、診断及び治療法の開発研究

  2023.04

  -

  Present

  AMED, ⼥性の健康の包括的⽀援実⽤化研究事業, Research grant, Coinvestigator(s)

• 新規心不全薬の効果比較：薬物反応性および機序解明に向けた統合オミックス解析の実施

  2023.04

  -

  2024.03

  慶應義塾, 学事振興資金, Research grant, Principal investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide 】

Intellectual Property Rights, etc. 【 Display / hide 】

• 医用情報処理装置、医用情報処理方法、医用情報処理プログラム、及び医用情報処理システム（心電図機械学習を用いた心血管疾患の診療支援システム）

  Date applied： 特願2020-167287  2020.10 

  Date announced： 特開2022-059494  2022.04 

  Date issued： 特許第7558556号 

  Date registered： 2024.09

  Patent, Joint

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• 第86回 日本循環器学会学術集会 Young Investigator's Award: Clinical Research

  2022.03

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 第38回 東京CCU研究会 殊勲賞

  2018.12

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 第13回 日本心臓リハビリテーション学会学術集会 Young Investigator's Award

  2016.09

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 第33回 東京CCU研究会 最優秀演題賞

  2013.12

  Type of Award： Award from Japanese society, conference, symposium, etc.

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• THEORETICAL ISSUES IN CANCER MEDICATION NURSING

  2024

• LECTURE SERIES, INTERNAL MEDICINE (CARDIOLOGY)

  2024

• LECTURE SERIES, INTERNAL MEDICINE (CARDIOLOGY)

  2023

• がん薬物療法看護論

  2023

  腫瘍循環器学

• LECTURE SERIES, INTERNAL MEDICINE (CARDIOLOGY)

  2022

display all >>

Courses Previously Taught 【 Display / hide 】

Courses Previously Taught 【 Display / hide 】

• 内科学（循環器）

  慶應義塾大学

  2021.04

  -

  Present

  , 

  Undergraduate (specialized), Lecture, Within own ｆaculty

• 医学概論（修士課程）

  慶應義塾大学大学院

  2020.04

  -

  2021.03

  , 

  Lecture

Memberships in Academic Societies 【 Display / hide 】

Memberships in Academic Societies 【 Display / hide 】

• 日本内科学会, 

  2010.04

  -

  Present

• 日本循環器学会, 

  2011.04

  -

  Present

• 日本心臓病学会, 

  2012.04

  -

  Present

• 日本心不全学会, 

  2016.04

  -

  Present

• 日本心臓リハビリテーション学会, 

  2017.04

  -

  Present

display all >>

Committee Experiences 【 Display / hide 】

Committee Experiences 【 Display / hide 】

• 2024.10

  -

  Present

  代議員, 日本心不全学会

• 2024.10

  -

  Present

  J-NECST委員（Japanese NEtwork for Cardiology Specialists of Tomorrow）, 日本心臓病学会

• 2023.04

  -

  Present

  心不全診療ガイドライン2025作成班 協力員, 日本循環器学会

• 2020.10

  -

  Present

  関東甲信越支部 学術委員会 委員, 日本循環器学会